Gravx

Granix (tbo-filgrastim) Injection for Subcutaneous Use

Granix is a medication designed to reduce the duration of severe neutropenia in adult and pediatric patients 1 month and older who are receiving myelosuppressive anticancer drugs. It works by stimulating the production of white blood cells, specifically neutrophils, which helps to prevent infections.

Key Information:

• Indication: Reduces severe neutropenia in patients with non-myeloid malignancies.
• Dosage: The recommended dose is 5 mcg/kg per day, administered subcutaneously. The first dose should be given no earlier than 24 hours after chemotherapy, and daily dosing should continue until the neutrophil count recovers to normal.
• Administration: The prefilled syringe should be injected subcutaneously. The needle guard will activate after the entire contents are injected.
• Contraindications: Granix is contraindicated in patients with a history of serious allergic reactions to filgrastim or pegfilgrastim products.
• Warnings: It can cause splenic rupture, acute respiratory distress syndrome, serious allergic reactions, and other complications. It is also associated with potential tumor growth stimulatory effects on malignant cells, particularly in patients with breast and lung cancer.

Product Details:

• Form: Available as a clear, colorless, preservative-free solution in single-dose prefilled syringes (300 mcg/0.5 mL and 480 mcg/0.8 mL) and vials (300 mcg/mL and 480 mcg/1.6 mL).
• Usage: Administered subcutaneously to help manage severe neutropenia in patients undergoing chemotherapy.

Patient Information:

• FDA-Approved Labeling: For detailed patient information and instructions for use, refer to the FDA-approved patient labeling.
• Counseling: Patients should be advised to read the patient information and instructions for use carefully.